Plasma Homocysteine as a Potential Marker of Early Renal Function Decline in IgA Nephropathy

Frontiers in Medicine

article

Yan-Na Wang¹  Han Xia⁵  Zhuo-Ran Song¹  Xu-Jie Zhou¹  Hong Zhang¹ 

[1] Renal Division, Peking University First Hospital;Peking University Institute of Nephrology;Key Laboratory of Renal Disease, Ministry of Health of China;Key Laboratory of Chronic Kidney Disease Prevention and Treatment ,(Peking University), Ministry of Education;Renal Division, Xingtai City People's Hospital

关键词: IgA nephropathy;    homocysteine;    chronic kidney disease;    primary glomerular diseases;    kidney disease progression;   

DOI  :  10.3389/fmed.2022.812552

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Hyperhomocysteinemia (HHcy) is very common among patients with chronic kidney disease (CKD), and related to the risk of cardiovascular events and mortality in these patients. However, the prevalence of HHcy in primary causes of CKD and its role in kidney disease progression are not well-understood. In this study, we investigated the prevalence of HHcy in different CKD stages in 221 patients with IgA nephropathy (IgAN) and 194 patients with other primary glomerular diseases. We also evaluated the association of homocysteine (Hcy) [after adjusted for estimated glomerular filtration rate (eGFR)] with CKD progression event, defined as ESKD or 50% decline in eGFR, in a cohort of 365 patients with IgAN. The prevalence of HHcy was 67.9% (150/221), 53.5% (76/142), 51.5% (17/33), and 42.1% (8/19) in patients with IgAN, membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, respectively. The Hcy/eGFR ratio was significantly associated with pathologic features of IgAN, including the proportion of global glomerulosclerosis ( r = 0.38, p 1.79. Our findings suggest that elevated Hcy/eGFR ratio may be an early marker of poor renal outcome in IgAN.

【 授权许可】

CC BY